Thryv raises $30M Series B to expand heart drug into heart failure
What's the deal? ThryvDealroom has a profile for this one. Try Dealroom → Therapeutics, a San Francisco clinical-stage biotech, has raised a $30 million Series B to launch ASPIRE-HF, a Phase 2a study of its lead drug THRV-1268 in heart-failure patients. InClin, a global contract research organisation, led the round, with support from existing investors.
What's the endgame? Thryv develops precision therapies targeting serum glucocorticoid inducible kinase 1 (SGK1), an enzyme implicated in inherited channelopathies, cardiometabolic diseases, and cardiomyopathies. The proceeds fund ASPIRE-HF, which tests THRV-1268 in adults with symptomatic heart failure with reduced ejection fraction (HFrEF) and QTc prolongation—a high-risk population facing electrical instability and sudden cardiac death. Enrollment opens in early 2027.
Why now? The raise follows a clinical milestone: Thryv completed enrollment of the first efficacy cohort in its Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome, with data expected in early 2027. In the third quarter of 2026, an Independent Data Monitoring Committee reviewed Wave II data and recommended continuing without changes.
Who's backing it? InClin joins as a strategic investor, bringing clinical operating capability alongside capital; it has helped Thryv establish operations in Australia for the ASPIRE-HF study. Returning backers include Fonds de solidarité FTQDealroom has a profile for this one. Try Dealroom →, Amplitude VenturesDealroom has a profile for this one. Try Dealroom →, Investissement Québec, Lumira VenturesDealroom has a profile for this one. Try Dealroom →, adMare BioInnovationsDealroom has a profile for this one. Try Dealroom →, CTI Life Sciences Fund, and Alexandria Venture InvestmentsDealroom has a profile for this one. Try Dealroom →.
What's management saying? "ASPIRE-HF is the culmination of years of work to establish SGK1 as a therapeutic target," said chief medical officer Amy Sehnert. She said Phase 1 results showing QT interval shortening in obese individuals supported expanding into heart failure.
What could go wrong? The financing funds a second indication while the company still awaits efficacy evidence in Long QT. ASPIRE-HF is early stage, double-blind and placebo-controlled, with a pre-specified efficacy read at Week 6 and a 24-week treatment period—so the money signals continued backing for the approach, not proof that it works.
The signal: At $30 million, Thryv's round sits in the 35th percentile by size, modest against recent cardiovascular biotech raises such as AnaCardioDealroom has a profile for this one. Try Dealroom →'s €62.5 million Series B and CardurionDealroom has a profile for this one. Try Dealroom →'s $260 million round. But the timing is notable: investors are funding a narrower, higher-risk heart-failure trial rather than a broad one, betting on a mechanism before the pivotal data lands.
Read more: prnewswire.com
Image credit: Thryv
